Synapse - Janine Pichardo

Results (41)

Hairy cell leukemia expresses programmed death-1

Research Letter

Kumar, P.; Gao, Q.; Chan, A.; Lewis, N.; Sigler, A.; Pichardo, J.; Xiao, W.; Roshal, M.; Dogan, A.
Blood Cancer Journal (2020)

Fulltext@MSK | Save

Genetic basis for iMCD-TAFRO

Journal Article

Yoshimi, A.; Trippett, T. M.; Zhang, N.; Chen, X.; Penson, A. V.; Arcila, M. E.; Pichardo, J.; Baik, J.; Sigler, A.; Harada, H.; more...
Oncogene (2020)

Fulltext@MSK | Save

Bright PD-1 expression by flow cytometry is a powerful tool for diagnosis and monitoring of angioimmunoblastic T-cell lymphoma

Journal Article

Yabe, M.; Gao, Q.; Ozkaya, N.; Huet, S.; Lewis, N.; Pichardo, J. D.; Moskowitz, A. J.; Horwitz, S. M.; Dogan, A.; Roshal, M.
Blood Cancer Journal (2020)

Fulltext@MSK | Save

Lymphocyte-to-monocyte ratio may serve as a better prognostic indicator than tumor-associated macrophages in DLBCL treated with rituximab

Journal Article

Matsuki, E.; Bohn, O. L.; El Jamal, S.; Pichardo, J. D.; Zelenetz, A. D.; Younes, A.; Teruya-Feldstein, J.
Applied Immunohistochemistry & Molecular Morphology (2019)

Fulltext@MSK | Save

PICALM-MLLT10 fusion commonly presents with extramedullary acute leukemia and often with a mixed phenotype (MPAL)

Meeting Abstract

Tashkandi, H.; Xiao, W.; Roshal, M.; Zhang, Y.; Arcila, M.; Benayed, R.; Sen, F.; Ho, C.; Baik, J.; Pichardo, J.; more...
Modern Pathology (2019)

Fulltext@MSK | Save

PICALM-MLLT10 fusion commonly presents with extramedullary acute leukemia and often with a mixed phenotype (MPAL)

Meeting Abstract

Tashkandi, H.; Xiao, W.; Roshal, M.; Zhang, Y.; Arcila, M.; Benayed, R.; Sen, F.; Ho, C.; Baik, J.; Pichardo, J.; more...
Laboratory Investigation (2019)

Fulltext@MSK | Save

Clinical presentation determines selection of patients for initial observation in mantle cell lymphoma

Journal Article

Kumar, A.; Ying, Z.; Alperovich, A.; Dogan, A.; Hamlin, P.; Moskowitz, C.; Pichardo, J.; Portlock, C.; Sha, F.; Zelenetz, A. D.; more...
Haematologica (2019)

Fulltext@MSK | Save

Selinexor, a first-in-class XPO1 inhibitor, is efficacious and tolerable in patients with myelodysplastic syndromes refractory to hypomethylating agents

Meeting Abstract

Taylor, J.; Coleman, M.; Alvarez, K.; Pichardo, J.; Sen, F.; Chung, S. S.; Rampal, R. K.; Park, J. H.; Stein, E. M.; Tallman, M. S.; more...
Blood (2018)

Fulltext@MSK | Save

Initial results of a phase II study of sequential chemotherapy and lenalidomide followed by rituximab and lenalidomide maintenance for untreated mantle cell lymphoma